
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
IQVIA Holdings is experiencing notable growth in its Functional Service Provider (FSP), Real World Evidence (RWE), and Commercial Solutions and Medical Services (CSMS) segments, all of which demonstrated year-over-year growth in the third quarter. The company is benefiting from improved client decision timelines and a robust pipeline, bolstered by recent drug launches, which enhances its commercial momentum. Additionally, IQVIA's positive outlook is further supported by an anticipated growth rate of over 4% for its Research and Development Solutions (R&DS) segment on a constant currency basis, alongside an improved pricing environment.
Bears say
The financial analysis of IQVIA Holdings reveals a concerning trend in year-over-year constant currency (CC) growth, which has declined from 6.8% in the previous quarter to 3.8%, signaling a potential slowdown in revenue growth against tough comparisons. The company has expressed disappointment over any projected revenue growth falling below 5% for 2026, raising doubts about its ability to meet market expectations amid increasing challenges. Additionally, the impact of rising interest rates poses a risk to earnings, further complicating the outlook for IQVIA and contributing to a cautious perspective on its financial performance.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares